PK-R: A Potential Drug Target for Neuronal and Psychiatric Disorders

Target Name: Prokineticin Receptor (PK-R)

NCBI ID: P39403

Prokineticin Receptor (PK-R)

Other Name(s): GPR73 | Prokineticin Receptor | PK-R

PK-R: A Potential Drug Target for Neuronal and Psychiatric Disorders

Prokineticin Receptor (PK-R), also known as GPR73, is a protein that is expressed in various tissues throughout the body. It is a member of the G protein-coupled receptor (GPCR) family and is responsible for transmitting signals from the cell surface to inside the cell. PK-R has been identified as a potential drug target and has been shown to play a role in various physiological processes.

The PK-R gene was first identified in 1995 and has since been shown to encode a protein that is similar to the extracellular domain of the neurotransmitter GABA (纬-aminobutyric acid). PK-R is expressed in the brain and is thought to play a role in the regulation of neuronal excitability.

PK-R has been shown to play a role in a variety of physiological processes, including neuronal communication, learning and memory, and stress response. For example, studies have shown that PK-R is involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. PK-R has also been shown to play a role in the regulation of pain perception and the modulation of anxiety and depression.

Due to its involvement in a variety of physiological processes, PK-R has been identified as a potential drug target. Several studies have shown that blocking PK-R with small molecules has the potential to treat a range of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression.

One of the reasons for the potential of PK-R as a drug target is its expression in multiple brain regions and its involvement in a variety of cellular processes. This makes it difficult to target the receptor with small molecules, as the effects of the drug may be difficult to predict. Additionally, PK-R is known to be involved in multiple signaling pathways, which can make it difficult to identify potential drug targets.

Despite the challenges, several studies have shown that PK-R can be targeted with small molecules. One of the most promising compounds that has been shown to interact with PK-R is a small molecule called PF-81726. This compound was shown to block the activity of PK-R and to have therapeutic effects on a variety of neurological and psychiatric disorders, including Alzheimer's disease and depression.

Another compound that has been shown to interact with PK-R is a peptide called CRISPR-Cas9. This peptide is derived from the immune system and has been shown to have targeting potential for PK-R. Studies have shown that CRISPR-Cas9 can be used to knockdown the expression of PK-R and to improve the therapeutic effects of PF-81726 in animal models of Alzheimer's disease.

In addition to small molecules, researchers have also shown that other types of drugs, such as antibodies and kinetic modulators, can be used to target PK-R. Drugs that regulate enzyme activity.

PK-R has also been shown to be involved in several diseases, including cancer. Studies have shown that PK-R is involved in the regulation of cell division and that it can contribute to the development and progression of cancer. This makes it a potential target for anti-cancer drugs.

In conclusion, Prokineticin Receptor (PK-R) is a protein that is involved in a variety of physiological processes and has been identified as a potential drug target. The development of small molecules and other types of drugs that can interact with PK-R is a promising direction for future research in this field. Further studies are needed to fully understand the role of PK-R in

Protein Name: Prokineticin Receptor (PK-R) (nonspecified Subtype)

The "Prokineticin Receptor (PK-R) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Prokineticin Receptor (PK-R) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets